Aims Dapagliflozin improves the prognosis of patients with heart failure (HF), regardless of
left ventricular ejection fraction (LVEF). However, its effect on cardiac remodelling …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background: The impact of heart failure (HF) duration on outcomes and treatment effect is
largely unknown. We aim to compare baseline patient characteristics, outcomes, and the …

Aims Patients with heart failure experience a high burden of symptoms and physical
limitations, and poor quality of life. Dapagliflozin reduces heart failure hospitalization and …

Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of
worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Aims This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of
dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF)> 40% varied by …

Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure
(HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This …